TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorTreeline Biosciences, Inc.
About this trial
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Eligibility criteria
Qualifiers
Participant must have measurable disease at study entry
Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy.
FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.
Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).
Disqualifiers
Participants must not have current central nervous system (CNS) involvement. Participants with past history of CNS involvement of lymphoma must have had CNS disease fully treated with no evidence of recurrence within 12 months.
Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days prior to the start of the study.
Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.
Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
Trial design
Treatments tested in this trial
- TLN-121
- TLN-254
- TLN-121
Treatment groups
180 Participants
are divided into 2 treatment groupsLocations
12Australia
Macquarie University Hospital2113, Macquarie ParkNew South Wales, Australia
Princess Alexandra Hospital4102, WoolloongabbaQueensland, Australia
Cabrini Health3144, MalvernVictoria, Australia
Peter MacCallum Cancer Centre MelbourneVictoria, Australia
Sponsors and collaborators
Treeline Biosciences, Inc.
Lead sponsor
Source ClinicalTrials.gov